Nfe2L2 — Nuclear Factor Erythroid 2 Related Factor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | Nuclear Factor Erythroid 2-Related Factor 2 |
|---|---|
| Synonyms | Nrf2, NRF2, NFE2L2 |
| Chromosome | 2q31 |
| NCBI Gene ID | 4780 |
| OMIM | 604992 |
| Ensembl ID | ENSG00000116044 |
| UniProt ID | Q16236 |
| Protein | [NFE2L2 Protein](/proteins/nfe2l2-protein) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke |
NFE2L2 (Nuclear Factor Erythroid 2-Related Factor 2), commonly known as Nrf2, is a master transcriptional regulator of cellular antioxidant and cytoprotective responses. It is a basic leucine zipper (bZIP) transcription factor that controls the expression of a large network of antioxidant response element (ARE)-containing genes involved in detoxification, redox homeostasis, and stress resistance. Nrf2 is constitutively expressed in neurons and glia and plays a critical role in protecting the brain from oxidative stress, neuroinflammation, and protein aggregation—all hallmarks of neurodegenerative diseases.
Nrf2 is the master regulator of the cellular antioxidant response. Under homeostatic conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. Upon exposure to oxidative stress or electrophilic compounds, Nrf2 escapes Keap1-mediated repression, translocates to the nucleus, and heterodimerizes with small Maf proteins. This complex binds to ARE sequences in the promoter regions of target genes, driving their transcription.
Nrf2 regulates over 200 target genes, including:
Nrf2 is expressed in all brain cell types, including:
Nrf2 activity declines with age and in AD brains. Amyloid-beta (Aβ) plaques and neurofibrillary tangles are associated with impaired Nrf2 signaling. Genetic or pharmacologic Nrf2 activation:
Nrf2 dysfunction contributes to dopaminergic neuron vulnerability:
Nrf2 signaling is impaired in ALS:
Mutant huntingtin (mHTT) interferes with Nrf2:
Nrf2 is neuroprotective in acute brain injury:
| Compound | Mechanism | Clinical Status | References |
|---|---|---|---|
| Dimethyl fumarate (Tecfidera) | Covalent Keap1 modification | Approved for MS, trials for AD/PD | [1] |
| Sulforaphane | Covalent Keap1 modification | Clinical trials for AD/PD | [2] |
| Bardoxolone methyl | Nrf2 activation via Keap1 | Clinical trials for CKD, AD | [3] |
| Oltipraz | Nrf2 activation | Clinical trials for cancer, AD | [4] |
| Protandim | Nrf2 activation | Dietary supplement | [5] |
The study of Nfe2L2 — Nuclear Factor Erythroid 2 Related Factor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Linker RA, et al. FASEB J. 2011;25(2):500-512. PMID:20858610
[2] Zhang Y, et al. J Neurosci. 2017;37(1):106-119. PMID:28077727
[3] Pergande M, et al. Nat Rev Drug Discov. 2021;20(3):201-218. PMID:33608628
[4] Kwak MK, et al. Annu Rev Pharmacol Toxicol. 2021;61:505-525. PMID:33263306
[5] Nelson SK, et al. J Neurosci. 2006;26(42):10582-10588. PMID:17035530